Concentration-Dependent Synergy and Antagonism of Linezolid and Moxifloxacin in the Treatment of Childhood Tuberculosis: The Dynamic Duo

Optimal Clinical Doses of Faropenem, Linezolid, and Moxifloxacin in Children With Disseminated Tuberculosis: Goldilocks

(2016) Shashikant Srivastava et al.   CLINICAL INFECTIOUS DISEASES

A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way

(2016) Devyani Deshpande et al.   CLINICAL INFECTIOUS DISEASES

Linezolid for Infants and Toddlers With Disseminated Tuberculosis: First Steps

(2016) Devyani Deshpande et al.   CLINICAL INFECTIOUS DISEASES

Drug Concentration Thresholds Predictive of Therapy Failure and Death in Children With Tuberculosis: Bread Crumb Trails in Random Forests

(2016) Soumya Swaminathan et al.   CLINICAL INFECTIOUS DISEASES

A Long-term Co-perfused Disseminated Tuberculosis-3D Liver Hollow Fiber Model for Both Drug Efficacy and Hepatotoxicity in Babies

(2016) Shashikant Srivastava et al.   EBioMedicine

Towards early inclusion of children in tuberculosis drugs trials: a consensus statement

(2015) Sharon Nachman et al.   LANCET INFECTIOUS DISEASES

Determination of in vitro synergy between linezolid and other antimicrobial agents against Mycobacterium tuberculosis isolates

(2015) Lin Zou et al.   TUBERCULOSIS

Impact of Nonlinear Interactions of Pharmacokinetics and MICs on Sputum Bacillary Kill Rates as a Marker of Sterilizing Effect in Tuberculosis

(2014) Emmanuel Chigutsa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics and Safety of Moxifloxacin in Children With Multidrug-Resistant Tuberculosis

(2014) Stephanie Thee et al.   CLINICAL INFECTIOUS DISEASES

Subtherapeutic concentrations of first-line anti-TB drugs in South African children treated according to current guidelines: the PHATISA study

(2014) H. Hiruy et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes

(2013) J. G. Pasipanodya et al.   JOURNAL OF INFECTIOUS DISEASES

A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial Culture

(2012) E. Chigutsa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Modeling early bactericidal activity in murine tuberculosis provides insights into the activity of isoniazid and pyrazinamide

(2012) J. Grosset et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Dose-Dependent Activity of Pyrazinamide in Animal Models of Intracellular and Extracellular Tuberculosis Infections

(2011) Zahoor Ahmad et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetic Mismatch Does Not Lead to Emergence of Isoniazid- or Rifampin-Resistant Mycobacterium tuberculosis but to Better Antimicrobial Effect: a New Paradigm for Antituberculosis Drug Scheduling

(2011) Shashikant Srivastava et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Moxifloxacin Pharmacokinetics/Pharmacodynamics and Optimal Dose and Susceptibility Breakpoint Identification for Treatment of Disseminated Mycobacterium avium Infection

(2010) D. Deshpande et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Linezolid concentrations in infected soft tissue and bone following repetitive doses in diabetic patients with bacterial foot infections

(2010) Friederike Traunmüller et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Pharmacokinetics and Distribution of Linezolid in Cerebrospinal Fluid in Children and Adolescents

(2010) Ram Yogev et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Paradoxical Effect of Isoniazid on the Activity of Rifampin-Pyrazinamide Combination in a Mouse Model of Tuberculosis

(2009) D. Almeida et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetics of Moxifloxacin in Cerebrospinal Fluid and Plasma in Patients with Tuberculous Meningitis

(2009) J. W. C. Alffenaar et al.   CLINICAL INFECTIOUS DISEASES